Lipiodol Earns FDA Approval for Tumor Imaging in HCC

Share this content:
Lipiodol Earns FDA Approval for Tumor Imaging in HCC
Lipiodol Earns FDA Approval for Tumor Imaging in HCC

The US Food and Drug Administration (FDA) has approved Guerbet's Lipiodol (ethiodized oil) injection for hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC), according to a press release from the manufacturer.

In October 2013, the FDA granted Lipiodol Orphan Drug Designation for management of patients with HCC.

For the past 3 years, Lipiodol has been supplied via a temporary importation program. The FDA, however, recently approved a new manufacturing site for US distribution, and Guerbet plans to transition from the importation program once product from the newly approved manufacturing site is available in the US, according to information in the release.

RELATED: Gastrointestinal Cancers Resource Center

Lipiodol is contraindicated in patients with a hypersensitivity to the agent, hyperthyroidism, traumatic injuries, or recent hemorrhage or bleeding.

"The additional indication approved by FDA is a major milestone on the ambitious approach taken by the company to keep the product accessible for US patients to assist in the management of this devastating disease,” Corina Harper, Guerbet Director of North America Medical and Regulatory Affairs, said in the release.

“We are pleased to receive FDA authorization which assures continuous accessibility to this drug to many HCC patients across America", said Corina Harper, Guerbet Director of North America Medical and Regulatory Affairs.”

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs